900573-88-8
900573-88-8 structure
- Name: JI-101
- Chemical Name: 1-[1-[(2-aminopyridin-4-yl)methyl]indol-4-yl]-3-(5-bromo-2-methoxyphenyl)urea
- CAS Number: 900573-88-8
- Molecular Formula: C22H20BrN5O2
- Molecular Weight: 466.33100
- Catalog: Signaling Pathways Protein Tyrosine Kinase/RTK Ephrin Receptor
- Create Date: 2017-03-13 00:03:51
- Modify Date: 2024-01-30 21:42:53
-
JI-101 is an orally available multi-kinase inhibitor of VEGFR2，PDGFRβ and EphB4 with potent anti-cancer activity.
| Name | 1-[1-[(2-aminopyridin-4-yl)methyl]indol-4-yl]-3-(5-bromo-2-methoxyphenyl)urea |
|---|---|
| Synonyms |
ji-101
unii-980m4n37dh cgi-1842 |
| Description | JI-101 is an orally available multi-kinase inhibitor of VEGFR2，PDGFRβ and EphB4 with potent anti-cancer activity. |
|---|---|
| Related Catalog | |
| Target |
VEGFR2 PDGFRβ |
| In Vitro | JI-101 is found to be stable in all preclinical and human liver microsomes. The % metabolized is ranged between 3.03-3.95 across the tested species liver microsomes. The % metabolized is relatively higher in mice liver microsomes followed by dog, human and rat liver microsomes[1]. |
| In Vivo | JI-101excreted through bile along with its mono- and di-hydroxy metabolites. Following oral administration, JI-101 is rapidly absorbed, reaching Cmax within 2 h. The t1/2 of JI-101 with intravenous and oral route is found to be 1.75±0.79 and 2.66±0.13 h, respectively. The Cl and Vd by intravenous route for JI-101 are found to be 13.0±2.62 mL/min/kg and 2.11±1.42 L/kg, respectively. The tissue distribution of JI-101 is extensive with rapid and preferred uptake into lung tissue. Overall, the oral bioavailability of JI-101 is 55% and the primary route of elimination for JI-101 is feces[1]. |
| Animal Admin | Rats: Pharmacokinetics and bioavailability assessment of JI-101 are evaluated in a preliminary parallel-group study in male S.D. rats. Four rats (195–210 g) per route receive JI-101 at a dose of 3 and 30 mg/kg for i. v. (via tail vein) and oral dose (by gavage), respectively. Serial blood samples (100 μL) are collected from retro-orbital plexus at pre-dose, 0.12 ( i. v. only) 0.25, 0.5, 1, 2, 4, 8, 10 (oral only) and 24 h. Blood samples are collected in tubes containing K2 EDTA as the anticoagulant and centrifuged for 5 min maintained at 4 °C for plasma separation and stored frozen at −80±10 °C until analysis[1]. |
| References |
| Molecular Formula | C22H20BrN5O2 |
|---|---|
| Molecular Weight | 466.33100 |
| Exact Mass | 465.08000 |
| PSA | 98.42000 |
| LogP | 5.09860 |
| Storage condition | 2-8℃ |